[
  {
    "ts": null,
    "headline": "Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors",
    "summary": "Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=d6ce26545eff0e14ee8630c86cd5e90a15387df88829ae07649122450cd4026e",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750178160,
      "headline": "Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors",
      "id": 135357103,
      "image": "",
      "related": "GILD",
      "source": "MarketWatch",
      "summary": "Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=d6ce26545eff0e14ee8630c86cd5e90a15387df88829ae07649122450cd4026e"
    }
  },
  {
    "ts": null,
    "headline": "Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD",
    "summary": "NEW YORK, June 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Gilead Sciences, Inc.  . Such investors are advised to contact Danielle Peyton at...",
    "url": "https://finnhub.io/api/news?id=8ef5ce49c66811061dfae0933b88abcbc8a42096253a2ba2ea2dcadf9b6257b1",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750154498,
      "headline": "Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD",
      "id": 135327050,
      "image": "",
      "related": "GILD",
      "source": "Finnhub",
      "summary": "NEW YORK, June 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Gilead Sciences, Inc.  . Such investors are advised to contact Danielle Peyton at...",
      "url": "https://finnhub.io/api/news?id=8ef5ce49c66811061dfae0933b88abcbc8a42096253a2ba2ea2dcadf9b6257b1"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Researcher Awarded the AAAS Mani L. Bhaumik Breakthrough of the Year Award",
    "summary": "Gilead has been a leader in HIV innovation for decades. Now, we're proud to share that one of our researchers, Moupali Das, has been awarded the AAAS Mani L. Bhaumik Breakthrough of the Year Award for...",
    "url": "https://finnhub.io/api/news?id=5465d61bb8eed89411d648b0924fc142d6e7dac4b9a14302e096770505e70077",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750152490,
      "headline": "Gilead Researcher Awarded the AAAS Mani L. Bhaumik Breakthrough of the Year Award",
      "id": 135326704,
      "image": "",
      "related": "GILD",
      "source": "Finnhub",
      "summary": "Gilead has been a leader in HIV innovation for decades. Now, we're proud to share that one of our researchers, Moupali Das, has been awarded the AAAS Mani L. Bhaumik Breakthrough of the Year Award for...",
      "url": "https://finnhub.io/api/news?id=5465d61bb8eed89411d648b0924fc142d6e7dac4b9a14302e096770505e70077"
    }
  },
  {
    "ts": null,
    "headline": "Gilead (GILD) Downplays FDA Decision to Pause HIV Combination Trial over Safety Concern",
    "summary": "Gilead Sciences Inc. (NASDAQ:GILD) is one of the 12 best healthcare stocks to buy now. Nevertheless, the company suffered a significant setback after the US Food and Drug Administration put on hold studies of several of its HIV drugs on June 11. The FDA placed a hold on the HIV treatment trial of GS-1720 and […]",
    "url": "https://finnhub.io/api/news?id=aa00672f45eb1551d31611962d585cf420999be9c7d94143854ff23cc5b056c7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750141461,
      "headline": "Gilead (GILD) Downplays FDA Decision to Pause HIV Combination Trial over Safety Concern",
      "id": 135318015,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences Inc. (NASDAQ:GILD) is one of the 12 best healthcare stocks to buy now. Nevertheless, the company suffered a significant setback after the US Food and Drug Administration put on hold studies of several of its HIV drugs on June 11. The FDA placed a hold on the HIV treatment trial of GS-1720 and […]",
      "url": "https://finnhub.io/api/news?id=aa00672f45eb1551d31611962d585cf420999be9c7d94143854ff23cc5b056c7"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences : Russia EFPIA Report 2024 (in English) (gilead scineces efpia report 2024 in english russia)",
    "summary": "& D Gilead Sciences Russia EFPIA Report 2024 Date of publication: 30/06/2025 Full Name ...",
    "url": "https://finnhub.io/api/news?id=52ffab68cb75a9c0a64d408af0e5c0ae11de7f530fb46a1df7dc5d77911c911e",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750138930,
      "headline": "Gilead Sciences : Russia EFPIA Report 2024 (in English) (gilead scineces efpia report 2024 in english russia)",
      "id": 135324203,
      "image": "",
      "related": "GILD",
      "source": "Finnhub",
      "summary": "& D Gilead Sciences Russia EFPIA Report 2024 Date of publication: 30/06/2025 Full Name ...",
      "url": "https://finnhub.io/api/news?id=52ffab68cb75a9c0a64d408af0e5c0ae11de7f530fb46a1df7dc5d77911c911e"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences : Russia EFPIA Methodological Note 2024 (in English) (efpia methodological note 2024 eng)",
    "summary": "Methodological Note Contents Introduction 2 Definition of Transfers of Value 2 ...",
    "url": "https://finnhub.io/api/news?id=24b407b8c25fb372d6c3ca797a9b73f7e5b0dee82c2c933005f823c64b64ae88",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750138928,
      "headline": "Gilead Sciences : Russia EFPIA Methodological Note 2024 (in English) (efpia methodological note 2024 eng)",
      "id": 135324205,
      "image": "",
      "related": "GILD",
      "source": "Finnhub",
      "summary": "Methodological Note Contents Introduction 2 Definition of Transfers of Value 2 ...",
      "url": "https://finnhub.io/api/news?id=24b407b8c25fb372d6c3ca797a9b73f7e5b0dee82c2c933005f823c64b64ae88"
    }
  },
  {
    "ts": null,
    "headline": "Impax U.S. Sustainable Economy Fund Q1 2025 Commentary",
    "summary": "The Impax US Sustainable Economy Fund underperformed the Russell 1000 benchmark in the first quarter. Read more here.",
    "url": "https://finnhub.io/api/news?id=23bf52ec80349eb550b8386c0e65d9677b0d05d4d0653f2de803d342d61fd5fd",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750134720,
      "headline": "Impax U.S. Sustainable Economy Fund Q1 2025 Commentary",
      "id": 135322264,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2161001170/image_2161001170.jpg?io=getty-c-w1536",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "The Impax US Sustainable Economy Fund underperformed the Russell 1000 benchmark in the first quarter. Read more here.",
      "url": "https://finnhub.io/api/news?id=23bf52ec80349eb550b8386c0e65d9677b0d05d4d0653f2de803d342d61fd5fd"
    }
  }
]